Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 670-679

  Amuah, Joseph E ^a,b   Hogan, David B ^c   Eliasziw, Misha ^c   Supina, Alison ^c   Beck, Patricia ^d   Downey, Winanne ^d   Maxwell, Colleen J ^c  

^a CANADIAN INSTITUTE FOR HEALTH INFORMATION   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Saskatchewan Ministry of Health   (Canada)

Author keywords

Administrative database; Alzheimer's disease; Cholinesterase inhibitor; Cohort; Persistence

Indexed keywords

CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ACTIVITIES QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; CANADA; COHORT ANALYSIS; KAPLAN MEIER METHOD; NEUROPSYCHOLOGICAL TEST; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEUROPSYCHOLOGICAL TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SASKATCHEWAN; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; KAPLAN-MEIER ESTIMATE;

EID: 77955651041     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1946     Document Type: Article

References (53)

1. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia. 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008a; 179: 1019-1026.
2. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia. 4. Approach to management of mild to moderate dementia. CMAJ 2008b; 179: 787-793.
3. Herrmann N, Gauthier S. Diagnosis and treatment of dementia. 6. Management of severe Alzheimer disease. CMAJ 2008; 179: 1279-1287.
4. Herrmann N. Treatment of moderate to severe Alzheimer's disease: rationale and trial design. Can J Neurol Sci 2007; 34 (Suppl 1): S103-S108.
5. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 806-812.
6. Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-363.
7. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, for the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001; 58: 427-433.
8. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
9. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res 2006; 34: 339-347.
10. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009; 7: 74-83.
11. Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt H-P, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br Med J 2005; 331: 321-327.
12. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for AlzheimerTMs disease. Health Technol Assess 2006; 10(1): 1-160.
13. Jönsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 2003; 21: 1025-1037.
14. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 2000; 17: 351-360.
15. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52: 1138-1145.
16. Rosenblatt A, Samus QM, Onyike CU, et al. Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. Int J Geriatr Psychiatry 2008; 23: 178-184.
17. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibitors. J Am Geriatr Soc 2005; 53: 83-87.
18. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-944.
19. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging 2009; 26: 403-407.
20. Mucha L, Shaohung Wang S, Cuffel B, McRae T, Mark TL, del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 2008; 14: 451-461.
21. Sun Y, Lai M-S, Lu C-J, Chen R-C. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur J Neurol 2008; 15: 278-283.
22. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55: 1517-1523.
23. Suh D-C, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005; 22: 695-707.
24. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231-239.
25. Singh G, Thomas SK, Arcona SK, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc 2005; 53: 1269-1270.
26. Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN. Patterns of cholinesterase inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006; 4: 154-160.
27. Kogut SJ, El-Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 2005; 25: 1729-1735.
28. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alz Dis Assoc Dis 2002; 16: 49-51.
29. Downey W, Stang MR, Beck P, Osei W, Nichol J. Health services databases in Saskatchewan. In Pharmacoepidemiology (4th edn), Strom BL (ed.). John Wiley & Sons Ltd: Chichester, England, 2005; 295-310.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association: Washington, 1994.
31. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
32. Von Korff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
33. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-198.
34. Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37: 323-329.
35. Allison PD. Survival Analysis Using SAS1: A Practical Guide. SAS Institute, Inc.: Cary, NC, 1995.
36. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1, Art. No. CD001190.
37. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1, Art. No. CD005593.
38. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
39. Blais L, Kettani F-Z, Perreault S, Leroux J-C, Forget A, Kergoat M-J. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc 2009; 57: 366-368.
40. Starner CI, Gleason PP. Cholinesterase inhibitor utilization patterns: just because it can be counted does it mean it counts. J Manag Care Pharm 2008; 14: 462-464.
41. Ontario Ministry of Health and Long-Term Care. Handbook of Limited Use Drug Products, September 2005. (http://www.health.gov.on.ca/english/providers/ program/drugs/formulary/limited-use/limited-use-092705.pdf).
42. Morgan S, Raymond C, Mooney D, Martin D. The Canadian Rx Atlas (2nd edn). Centre for Health Services and Policy Research, University of British Columbia: Vancouver, BC, 2008; 76-81 (http://www.chspr.ubc.ca/rxatlas/canada).
43. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
44. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long term medication adherence. A study of the dynamics of statin use. Arch Intern Med 2007; 167: 847-852.
45. Höer A, Gothe H, Khan ZM, Schiffhorst G, Vincze G, Häussler B. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens 2007; 21: 744-746.
46. Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14: 795-803.
47. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-2713.
48. Goldman PD, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007; 298(1): 61-69.
49. Piette JD, Heisler M, Wagner TH. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures. J Clin Epidemiol 2006; 59: 739-746.
50. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-327.
51. Crystal S, Akincigil A, Bilder S,Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care 2007; 45: S58-S65.
52. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004; 11: e274-e285.
53. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44: 471-477.